Jeanne Mendell‐Harary

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

Koichiro Ogata, Jeanne Mendell‐Harary, Masaya Tachibana et al. · The Journal of Clinical Pharmacology · 2010 · 448 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).

Todd M. Bauer, Mrinal M. Gounder, Amy Weise et al. · Journal of Clinical Oncology · 2018 · 44 citations

Medicine, Oncology, Pharmacology +17

Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin

Ling He, Prachi Wickremasingha, James Lee et al. · Diabetes Research and Clinical Practice · 2014 · 24 citations

Pharmacy, Pharmacokinetics, Pharmacology +6

Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs).

Joachim von Pawel, Jennifer Tseng, Mircea Dediu et al. · Journal of Clinical Oncology · 2014 · 21 citations

Medicine, Oncology, Pharmacology +13

Nonlinear in Vitro-in Vivo Correlations

Jeanne Mendell‐Harary, James A. Dowell, Sian Bigora et al. · Advances in experimental medicine and biology · 1997 · 18 citations

Pharmacy, Pharmacokinetics, Pharmacodynamics +8